Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis

被引：0
|
作者：
Cook, S. [1 ]
Giovannoni, G. [2 ]
Leist, T. [3 ]
Syed, S. [4 ]
Nolting, A. [5 ]
Schick, R. [5 ]
机构：
[1] Rutgers State Univ, New Jersey Med Sch, Newark, NJ USA
[2] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[3] Thomas Jefferson Univ, Jefferson Med Coll, Div Clin Neuroimmunol, Philadelphia, PA 19107 USA
[4] EMD Serono Inc, Billerica, MA USA
[5] Merck KGaA, Darmstadt, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P875
引用
收藏
页码：465 / 466
页数：2
相关论文
共 50 条
  • [21] The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
    Rammohan, Kottil
    Coyle, Patricia K.
    Sylvester, Elke
    Galazka, Andrew
    Dangond, Fernando
    Grosso, Megan
    Leist, Thomas P.
    DRUGS, 2020, 80 (18) : 1901 - 1928
  • [22] Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis
    Comi, Giancarlo
    Hartung, Hans-Peter
    Kurukulasuriya, Nuwan C.
    Greenberg, Steven J.
    Scaramozza, Matthew
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (01) : 123 - 136
  • [23] The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
    Kottil Rammohan
    Patricia K. Coyle
    Elke Sylvester
    Andrew Galazka
    Fernando Dangond
    Megan Grosso
    Thomas P. Leist
    Drugs, 2020, 80 : 1901 - 1928
  • [24] The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
    Hermann, Robert
    Karlsson, Mats O.
    Novakovic, Ana M.
    Terranova, Nadia
    Fluck, Markus
    Munafo, Alain
    CLINICAL PHARMACOKINETICS, 2019, 58 (03) : 283 - 297
  • [25] The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
    Robert Hermann
    Mats O. Karlsson
    Ana M. Novakovic
    Nadia Terranova
    Markus Fluck
    Alain Munafo
    Clinical Pharmacokinetics, 2019, 58 : 283 - 297
  • [26] BUDGET IMPACT ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Dineva, T.
    Panayotov, P.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S205 - S205
  • [27] Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
    Moiola, Lucia
    Riva, Agostino
    Nicoletti, Ferdinando
    Uccelli, Antonio
    Salvetti, Marco
    Battistini, Luca
    Furlan, Roberto
    CURRENT NEUROPHARMACOLOGY, 2022, 20 (10) : 1811 - 1815
  • [28] Characteristics and Treatment Patterns of Patients with Multiple Sclerosis Initiating Cladribine Tablets in the United States
    Lobo, C.
    Lee, J.
    Chin, A.
    Lui, S.
    Chen, X.
    Evans, E.
    Phillips, A. L.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 192 - 193
  • [29] Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, With Particular Reference to Respiratory Viral Infections and COVID-19
    Giovannoni, Gavin
    Berger, Joseph
    Leist, Thomas
    Jack, Dominic
    Galazka, Andrew
    Nolting, Axel
    Damian, Doris
    NEUROLOGY, 2021, 96 (15)
  • [30] The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
    Butzkueven, Helmut
    Hillert, Jan
    Soilu-Hanninen, Merja
    Ziemssen, Tjalf
    Kuhle, Jens
    Wergeland, Stig
    Magyari, Melinda
    Berger, Joseph R.
    Moore, Nicholas
    Aydemir, Aida
    Bezemer, Irene
    Sabido, Meritxell
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (10) : 1367 - 1374
12345